Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies.

Autor:	Iacoboni G; Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain, Barcelona, Spain., Morschhauser F; University of Lille, Lille, France.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2024 Nov 14. Date of Electronic Publication: 2024 Nov 14.
DOI:	10.1182/blood.2024025699
Abstrakt:	Follicular lymphoma (FL) usually requires multiple lines of therapy and disease control remains largely insufficient with conventional chemoimmunotherapy. Several T-cell redirecting strategies recently approved in the relapsed/refractory setting have the potential to improve outcomes and change the treatment algorithm in FL. This review focuses on the role of chimeric antigen receptor T-cells and bispecific antibodies in FL, paying special attention to sequencing approaches and future directions. (Copyright © 2024 American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu